Respiratory syncytial virus infectious disease
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Infection with the respiratory syncytial virus, an RNA virus of the genus Pneumovirus, in the family Paramyxoviridae, which is characterized by the formation of syncytia in tissue culture. It causes minor respiratory infection with rhinitis and cough in adults, but is capable of causing severe bronchitis and bronchopneumonia in young children.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Respiratory syncytial virus infectious disease
- Therapeutic area
- Infectious Disease
- respiratory syncytial virus infectious disease
- Human respiratory syncytial virus infection
- respiratory syncytial virus infection
- infections, Human respiratory syncytial virus
- Disease mechanisms
- Acquired
- Severity
- Severe
- Infectious Disease
- Pulmonology
- MONDO ID
- MONDO:0001577
- Parent condition
- MONDO:0005856
Related records
Broader conditions (12)
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Mononegavirales infectious disease
- Primary viral infectious disease
- Respiratory system disorder
- Respiratory tract infectious disorder
- Viral infectious disease
- Viral respiratory tract infection
Narrower conditions (1)
- Respiratory syncytial virus bronchiolitis
Trials (302)
- A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.
- A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
- A Dose Finding Study of VN-0200
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
- A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants
- A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
- A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
- A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171
- A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America
- A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806
- A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults
- A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176
- A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older
- A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
- A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model
- A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
- A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
- A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
- A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children
- A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
Approved drugs (4)
- Nirsevimab
- Palivizumab
- Respiratory syncytial virus pre-fusion glycoprotein F
- Respiratory syncytial virus pre-fusion glycoprotein F mrna
Drugs in development (42)
- AD26.RSV.PREF Phase 3
- Aluminum hydroxide Phase 1
- Aluminum phosphate Phase 2
- ALX-0171 Phase 1
- Asvasiran sodium Phase 2
- Azithromycin Phase 2
- BTA-9881 Phase 1
- Clesrovimab Phase 3
- Cyclosporine Phase 1
- Dabigatran Phase 1
- Danirixin Phase 1
- Deuremidevir hydrobromide Phase 2
- Elasomeran Phase 3
- Fluconazole Phase 1
- Influenza virus vaccine Phase 3
- Itraconazole Phase 1
- JNJ-49095397 Phase 1
- Laduviglusib Phase 1
- Lumicitabine Phase 2
- Matrix-M1 adjuvant Phase 2
Other linked drugs (1)
- Plozalizumab